<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094417</url>
  </required_header>
  <id_info>
    <org_study_id>531-KR001</org_study_id>
    <nct_id>NCT02094417</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Korea Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be conducted to evaluate the efficacy and safety of AMG531 and to
      determine the recommended initial dose of AMG531 on the basis of its efficacy and safety when
      it is administered subcutaneously (SC) to the Aplastic Anemia (AA) patients with
      immunosuppressive-therapy refractory thrombocytopenia and also to assess the pharmacokinetics
      of this product. Its efficacy and safety during the extension period beyond one year will
      also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2014</start_date>
  <completion_date type="Actual">November 7, 2017</completion_date>
  <primary_completion_date type="Actual">April 24, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving a platelet response</measure>
    <time_frame>At week 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving a platelet response</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who become platelet transfusion independent</measure>
    <time_frame>156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving erythroid response</measure>
    <time_frame>156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving neutrophil response</measure>
    <time_frame>156 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) bleeding scale</measure>
    <time_frame>156 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of Pharmacokinetics</measure>
    <time_frame>Weeks 1, 4, and 8</time_frame>
    <description>Pharmacokinetic parameters, including time to maximum concentration (Tmax), maximum concentration (Cmax) and area under the curve (AUC)0-t, will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events</measure>
    <time_frame>156 weeks + 4 weeks follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of neutralizing antibody</measure>
    <time_frame>156 weeks + 4 weeks follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>AMG531 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG531 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG531 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG531 (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG531</intervention_name>
    <description>Subcutaneous, weekly injection</description>
    <arm_group_label>AMG531 (Dose 3)</arm_group_label>
    <arm_group_label>AMG531 (Dose 1)</arm_group_label>
    <arm_group_label>AMG531 (Dose 2)</arm_group_label>
    <arm_group_label>AMG531 (Dose 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who is diagnosed as AA and refractory to immunosuppressive therapy

          -  Platelet ≤ 30,000/μL

        Exclusion Criteria:

          -  Concurrent active infection not adequately responding to appropriate therapy

          -  HIV positivity

          -  Bone marrow reticulin grade of &gt; 1

          -  Clinically significant cardiac disease

          -  Arterial or venous thrombosis within the last 1 year before enrollment

          -  Other cause of thrombocytopenia

          -  AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)

          -  Uncontrolled diabetes

          -  Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG +
             cyclosporine within 6 months before starting study treatment and/or cyclosporine or
             anabolic hormone within 6 weeks before starting the study treatment

          -  History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other
             thrombopoietin (TPO)-receptor agonist

          -  Who plans to conduct hematopoietic stem cell transplantation within 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea, Republic of</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia, Aplastic</keyword>
  <keyword>Thrombopoietin</keyword>
  <keyword>Thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

